Develops gene-editing treatments for patients with sickle cell disease and other genetic diseases, using base editing and delivery technologies.
10-K for FY2025, filed Feb 24, 2026
Beam earns money from license agreements: customers pay upfront fees when received or due, and Beam earns the revenue as it fulfills the agreement's obligations.
10-K for FY2025, filed Feb 24, 2026The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration…View ↗
$139.7M
10-K for FY2025, filed Feb 24, 2026
$139.7M ↗
Beam seeks partnerships with other companies through its technology platform and has license agreements with customers.
10-K for FY2025, filed Feb 24, 2026
No. It lost $80M in FY2025.
10-Q for Q3 FY2026, filed Nov 3, 2026
−$134.4MView ↗
8-K, filed Mar 5, 2026
On March 2, 2026 (the “Termination Date”), Beam Therapeutics Inc. (the “Company”) and Bio Palette Co., Ltd. (“Bio Palette”) mutually…View ↗
Growing. Revenue grew 2.7x in 4 years, from $51.8M in FY2021 to $139.7M in FY2025, about 28% a year.
Stated disease priorities
The older report described programs across hematology, immunology/oncology, and genetic diseases; the latest report frames its lead-program priorities around hematology and genetic diseases.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 24, 2026We are advancing our base editing technology across three disease-area portfolios: hematology, immunology/oncology and genetic diseases. We…View ↗
We are currently prioritizing the lead programs in our hematology and genetic disease portfolios, each of which have the potential to…View ↗
Competes with Life Edit, Metagenomi, Revvity, Aurora Therapeutics, Mammoth Biosciences, YolTech Therapeutics, HuidaGene Therapeutics, Intellia Therapeutics, CRISPR Therapeutics, Vertex Pharmaceuticals, Genetix Biotherapeutics, Novartis Pharmaceuticals, Kamau Therapeutics, Fulcrum Therapeutics, Tessera Therapeutics, Cimeio Therapeutics, Agios Pharmaceuticals, Wave Life Sciences, Prime Medicine, and Moderna
10-K for FY2025, filed Feb 24, 2026There are several other companies utilizing base editing technology, including Life Edit (an ElevateBio company), Metagenomi, Revvity…View ↗
Loading...